title: Development of myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis in a patient receiving treatment with anti-tumor necrosis factor-α.
abstract: We report on a 33-year-old woman who presented with positive myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) during rheumatoid arthritis treatment with infliximab. She had a history of worsening arthralgia, and urinalysis showed the new occurrence of hematuria and proteinuria. Renal biopsy showed necrotizing crescentic glomerulonephritis. Immunosuppressive therapy and discontinuation of the infliximab therapy alleviated her arthralgia and improved the urinalysis results. We report this rare case in which an anti-tumor necrosis factor-α (TNF-α) agent for ANCA-associated systemic vasculitis was studied.
authors.affiliation: Kidney Center, Toranomon Hospital, 2-2-2 Toranomon, Minato Ward, Tokyo, 105-8470, Japan. daigoro-daigoro@hotmail.co.jp
authors.forename: Daigoro
authors.initials: D
authors.lastname: Hirohama
authors.forename: Junichi
authors.initials: J
authors.lastname: Hoshino
authors.forename: Eiko
authors.initials: E
authors.lastname: Hasegawa
authors.forename: Masayuki
authors.initials: M
authors.lastname: Yamanouchi
authors.forename: Noriko
authors.initials: N
authors.lastname: Hayami
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Suwabe
authors.forename: Naoki
authors.initials: N
authors.lastname: Sawa
authors.forename: Fumi
authors.initials: F
authors.lastname: Takemoto
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Ubara
authors.forename: Shigeko
authors.initials: S
authors.lastname: Hara
authors.forename: Kenichi
authors.initials: K
authors.lastname: Ohashi
authors.forename: Kenmei
authors.initials: K
authors.lastname: Takaichi
mesh_terms: D000284:Administration, Oral; D000328:Adult; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D057915:Drug Substitution; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D007275:Injections, Intravenous; D007668:Kidney / Q000098:blood supply / Q000187:drug effects / Q000276:immunology; D007674:Kidney Diseases / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D008775:Methylprednisolone / Q000627:therapeutic use; D009195:Peroxidase / Q000276:immunology; D011239:Prednisolone / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014657:Vasculitis / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D005938:Glucocorticoids; D014409:Tumor Necrosis Factor-alpha; D011239:Prednisolone; D000069285:Infliximab; D009195:Peroxidase; D008775:Methylprednisolone